Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Brivanib_alaninate> ?p ?o. }
Showing items 1 to 57 of
57
with 100 items per page.
- Brivanib_alaninate abstract "Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Hepatocellular carcinoma is a primary cancer of the liver and is more common in men than in women. The disease occurs mostly in people who have scarring of the liver (cirrhosis) or after infection with hepatitis B or hepatitis C. Symptoms include pain and swelling in the abdomen, weight loss, weakness, loss of appetite and nausea. Hepatocellular carcinoma is a severe and life-threatening disease that is associated with poor overall survival. While the choice of treatment depends mainly on how advanced the disease is, the only proven therapies to cure the cancer is surgery to remove the tumor and liver transplantation, but these therapies can only be carried out in very few patients. Other treatments include chemotherapy and immunotherapy. Radiofrequency ablation and ethanol injection are also used to remove small tumors.As a result of poor liver function, metastases, or both, only 10% to 20% of patients undergo surgery. In patients having surgery, the 5-year survival rate is only 25% to 50%. Several chemotherapeutic agents have been evaluated for the treatment of hepatocellular carcinoma. Doxorubicin (trade name Adriamycin; also known as hydroxydaunorubicin), the most widely used agent in HCC, has shown a 4% to 10.5% response rate in patients with HCC. Studies have shown that the overall response (OR) rate, but not overall survival (OS), doubles when doxorubicin was given in combination with cisplatin, IFN, and 5-fluorouracil. The multitargeted tyrosine kinase inhibitor sorafenib (trade name Nexavar), which inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, raf, c-kit, and flt-3, has been shown to inhibit HCC-induced proliferation and angiogenesis. Sorafenib has also been shown to provide a significant improvement in OS in patients with HCC. Based on these results, researchers concluded that this class of agents may be effective in the treatment of HCC. Brivanib alaninate also inhibits VEGFR and fibroblast growth factor receptors (FGFR), which is known to play a major role in the etiopathogenesis of HCC. To date, brivanib alaninate has been investigated in 29 studies, including more than 4,000 patients around the world.".
- Brivanib_alaninate atcPrefix "none".
- Brivanib_alaninate casNumber "649735-63-7".
- Brivanib_alaninate iupacName "(S)-(R)-1-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy)propan-2-yl 2-aminopropanoate".
- Brivanib_alaninate pubchem "11154925".
- Brivanib_alaninate thumbnail Brivanib_alaninate.svg?width=300.
- Brivanib_alaninate wikiPageExternalLink brivanib-alaninate.
- Brivanib_alaninate wikiPageExternalLink Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81850.
- Brivanib_alaninate wikiPageExternalLink WC500117965.pdf.
- Brivanib_alaninate wikiPageExternalLink www.oncozine.com.
- Brivanib_alaninate wikiPageID "34793637".
- Brivanib_alaninate wikiPageRevisionID "600700569".
- Brivanib_alaninate atcPrefix "none".
- Brivanib_alaninate c "22".
- Brivanib_alaninate casNumber "649735".
- Brivanib_alaninate chemspiderid "9330033".
- Brivanib_alaninate f "1".
- Brivanib_alaninate h "24".
- Brivanib_alaninate hasPhotoCollection Brivanib_alaninate.
- Brivanib_alaninate inchi "1".
- Brivanib_alaninate inchikey "LTEJRLHKIYCEOX-OCCSQVGLBD".
- Brivanib_alaninate iupacName "--1-propan-2-yl 2-aminopropanoate".
- Brivanib_alaninate legalStatus "Investigational new drug".
- Brivanib_alaninate molecularWeight "441.5".
- Brivanib_alaninate n "5".
- Brivanib_alaninate o "4".
- Brivanib_alaninate pubchem "11154925".
- Brivanib_alaninate routesOfAdministration "Oral".
- Brivanib_alaninate smiles "CC1=CC2=CC=CCOC3=NC=NN4C3=CC".
- Brivanib_alaninate stdinchi "1".
- Brivanib_alaninate stdinchikey "LTEJRLHKIYCEOX-OCCSQVGLSA-N".
- Brivanib_alaninate subject Category:Amino_acid_derivatives.
- Brivanib_alaninate subject Category:Bristol-Myers_Squibb.
- Brivanib_alaninate subject Category:Experimental_cancer_drugs.
- Brivanib_alaninate subject Category:Indoles.
- Brivanib_alaninate subject Category:Prodrugs.
- Brivanib_alaninate type Abstraction100002137.
- Brivanib_alaninate type AminoAcidDerivatives.
- Brivanib_alaninate type Calculation105802185.
- Brivanib_alaninate type Cognition100023271.
- Brivanib_alaninate type DerivedFunction106014730.
- Brivanib_alaninate type HigherCognitiveProcess105770664.
- Brivanib_alaninate type ProblemSolving105796750.
- Brivanib_alaninate type Process105701363.
- Brivanib_alaninate type PsychologicalFeature100023100.
- Brivanib_alaninate type Thinking105770926.
- Brivanib_alaninate type Drug.
- Brivanib_alaninate type FunctionalSubstance.
- Brivanib_alaninate comment "Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Hepatocellular carcinoma is a primary cancer of the liver and is more common in men than in women.".
- Brivanib_alaninate label "Brivanib alaninate".
- Brivanib_alaninate sameAs m.0j3ddsy.
- Brivanib_alaninate sameAs Q4971701.
- Brivanib_alaninate sameAs Q4971701.
- Brivanib_alaninate sameAs Brivanib_alaninate.
- Brivanib_alaninate wasDerivedFrom Brivanib_alaninate?oldid=600700569.
- Brivanib_alaninate depiction Brivanib_alaninate.svg.
- Brivanib_alaninate isPrimaryTopicOf Brivanib_alaninate.